Fusion Pharma: Fusion (FUSN) Up 99% on $2.4B Buyout Offer From AstraZeneca

AstraZeneca (AZN) is set to acquire Fusion Biopharma (FUSN) for $21 per share in cash, along with a contingent value right of $3 per share, tied to a regulatory milestone.